Mercaptopurine Alternatives Compared
| Mercaptopurine | Entyvio (vedolizumab) | Pentasa (mesalamine) |
|
|---|
| Mercaptopurine | Entyvio (vedolizumab) | Pentasa (mesalamine) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Crohn's Disease - Maintenance, Autoimmune Hepatitis, Crohn's Disease - Active, Acute Lymphoblastic Leukemia, Inflammatory Bowel Disease, Intestinal Arterial Insufficiency, Ulcerative... View more |
Prescription only
Entyvio infusion is an integrin receptor antagonist that may be used to reduce inflammation associated with moderate to severe ulcerative colitis or Crohn's disease. It targets the gut specifically... View more |
Prescription only
Prescribed for Ulcerative Colitis - Maintenance, Ulcerative Colitis - Active, Crohn's Disease - Maintenance, Inflammatory Bowel Disease, Ulcerative Colitis, Ulcerative Proctitis. Pentasa may also be... View more |
Related suggestions Crohn's Disease, Maintenance
|
|||||||||||||||||||||||
| More about Mercaptopurine | More about Entyvio (vedolizumab) | More about Pentasa (mesalamine) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Mercaptopurine has an average rating of 6.2 out of 10 from a total of 31 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 32% reported a negative effect. |
Entyvio has an average rating of 6.3 out of 10 from a total of 161 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 27% reported a negative effect. |
Pentasa has an average rating of 7.8 out of 10 from a total of 89 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 9% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Mercaptopurine prices |
View all Entyvio prices |
View all Pentasa prices |
||||||||||||||||||||||||
| Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Purinethol, Purixan | Other vedolizumab brands include: Entyvio Pen | Other mesalamine brands include: Apriso, Asacol, Asacol HD, Canasa, Canasa Pac, Delzicol, Lialda, Rowasa, Rowasa Sulfite Free, Zaldyon View more | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
2 hours |
600 hours |
10 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
Excluding Asacol And Asacol HD
Category C
Risk cannot be ruled out
Asacol And Asacol HD See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 293 drugs are known to interact with Mercaptopurine:
|
A total of 161 drugs are known to interact with Entyvio:
|
A total of 121 drugs are known to interact with Pentasa:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
September 11, 1953 |
May 20, 2014 |
May 10, 1993 |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.